Cefpodoxime: Difference between revisions

Line 23: Line 23:
***Children >12 years to adolescent: adult dosing  
***Children >12 years to adolescent: adult dosing  
**Acute sinusitis
**Acute sinusitis
***Infant ≥2 months to children <12 years: 5 mg/kg/dose (maximum 200 mg/dose) q 12 h for 10 days, ISDA recommend adding Clindamycin for 10-14 days in patients with failed initial therapy or at risk of antibiotic resistance (attending daycare, age <2 years, recently hospitalised, antibiotic used with in 1 month) <ref>Chow AW et.al. ISDA clinical practice guideline for acute bacterial rhino sinusitis in children and adult.Clinical Infect Dis.2012 Apr;54(8):e72-e112</ref>


==Special Populations==
==Special Populations==

Revision as of 14:39, 13 June 2016

General

  • Type: 3rd generation cephalosporin
  • Dosage Forms: tablet (100,200), suspension (50 mg/5ml, 100 mg/5ml)
  • Common Trade Names: Cefopodoxine Proxetil

Adult Dosing

  • Bronchitis (chronic), actue bacterial infection: 200 mg q 12 h for 10 days
  • Pharyngitis/Tonsillitis: 100 mg q 12 h for 5-10 days
  • Acute community acquired pneumonia: 200 mg q 12 h for 14 days
  • Acute rhino sinusitis: 200 mg q 12 h for 10 days
  • Skin and soft tissue infection: 400 mg q 12 h for 14 days
  • Urinary tract infection, uncomplicated: 100 mg q 12 h for 7 days

Pediatric Dosing

  • General range
    • Infant ≥2 months to children <12 years: 10 mg/kg/day (maximum 200 mg/dose) q 12 h
    • Children >12 years to adolescent: 100 to 400 mg q 12 h
  • Specific indication
    • Bronchitis (chronic), acute bacterial infection: adult dosing for Infant ≥2 months to children <12 years
    • Acute otitis media: Infant ≥2 months to children <12 years: 5 mg/kg/dose (maximum 200 mg/dose) q 12 h for 5 days, duration according to AAP recommendation [1]: for children < 2 years or any age with sever symptoms; 10 day-course, age 2-5 years with mild to moderate symptoms: 7 day-course; age ≥ 6 years with mild to moderate symptoms: 5 day-course
    • Pharyngitis/tonsillitis:
      • Infant ≥2 months to children <12 years: 5 mg/kg/dose (maximum 100 mg/dose) q 12 h for 5-10 days
      • Children >12 years to adolescent: adult dosing
    • Acute sinusitis
      • Infant ≥2 months to children <12 years: 5 mg/kg/dose (maximum 200 mg/dose) q 12 h for 10 days, ISDA recommend adding Clindamycin for 10-14 days in patients with failed initial therapy or at risk of antibiotic resistance (attending daycare, age <2 years, recently hospitalised, antibiotic used with in 1 month) [2]

Special Populations

  • Pregnancy Rating:
  • Lactation:
  • Renal Dosing
    • Adult
    • Pediatric
  • Hepatic Dosing
    • Adult
    • Pediatric

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life:
  • Metabolism:
  • Excretion:
  • Mechanism of Action:

See Also

Sources

  1. Lieberthal A. et al.The Diagnosis and Management of Acute Otitis Media.Pediatrics Mar 2013, 131 (3) e964-e999
  2. Chow AW et.al. ISDA clinical practice guideline for acute bacterial rhino sinusitis in children and adult.Clinical Infect Dis.2012 Apr;54(8):e72-e112